Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone crossover study of brown fat activity in adults with obesity risk
ACTRN12614001112651Phase 4Completed
- Sponsor
- Professor Ken Ho
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of spironolactone in obesity (2 arms), sponsored by Professor Ken Ho. Primary endpoints: Brown fat volume changes on 18FDG-PET-CT scan and Brown fat activity changes on PET-CT. Started Apr 2016; status: completed.
02
Drugs
spironolactone
03
Conditions
obesity
Beyond the preview
Go deeper on ACTRN12614001112651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614001112651.